Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

colorectal cancer

This page shows the latest colorectal cancer news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

or mismatch repair deficient (dMMR) metastatic colorectal cancer. ... About 4% to 5% of metastatic colorectal cancer patients have those mutations, and make them less likely to benefit from conventional chemotherapy.

Latest news

  • ACT immunotherapy cures terminal breast cancer patient ACT immunotherapy cures terminal breast cancer patient

    ACT immunotherapy cures terminal breast cancer patient. The new approach focuses on mutations rather than cancer type. ... The new study suggests that barrier could be overcome. Rosenberg says investigators have already tested the approach in liver and

  • Loxo, Bayer get quick FDA review for ‘precision’ cancer drug Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

    biomarker, a departure from the usual regulatory route of seeking approval based on the organ or tissue where the cancer starts to grow. ... NTRK fusions are seen in a broad range of tumour types, including various forms of colorectal, lung, thyroid,

  • Another IO knockback as Tecentriq combo fails phase III trial Another IO knockback as Tecentriq combo fails phase III trial

    cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population. ... In particular, we have a number of studies evaluating medicines in colorectal cancer that could

  • AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

    AstraZeneca’s PD-L1 inhibitor Imfinzi and Bavarian Nordic’s cancer vaccine CV301 will be combined in a phase I/II trial involving patients with metastatic colorectal or pancreatic cancers. ... Colorectal and pancreatic cancers are among the most

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    market. Growth has also come from a steady stream of new indications, including recent approvals in hepatocellular carcinoma, renal cell carcinoma and colorectal cancer. ... stable trends”in second-line lung cancer in the US and good growth elsewhere

More from news
Approximately 18 fully matching, plus 229 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.

  • Winning the war against cancer Winning the war against cancer

    data sources and the organisation of screening programmes for colorectal cancer. ... Cancer is an important disease to see [its] impact on the health system.

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to

  • Pharma deals during February 2014 Pharma deals during February 2014

    MK-3475 was awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. ... BATON studies in colorectal cancer and metastatic triple negative breast cancer.

  • The oncology market in Canada The oncology market in Canada

    on the other side of the border, three tumours have comparable incidence rates, while colorectal cancer is a distant number four. ... Colorectal cancer. Colorectal cancer is where the two countries demonstrate the most substantial differences.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • 90TEN nominated for five Communiqué Awards

    Meanwhile two of the agency’ s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated

  • Lynch syndrome: a patient perspective

    My grandfather was probably the first in the family to be afflicted with Lynch syndrome or Hereditary Nonpolyposis Colorectal Cancer (HNPCC). ... A revolutionary discovery. For my father, the cancer came back four more times.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Quick links

Infographics

Multimedia